Form 4: Indivior CFO Ryan Preblick's RSU Vesting and Tax Sale

Indivior Pharmaceuticals CFO Ryan Preblick reported the vesting of 6,302 restricted stock units and the subsequent sale of 2,843 shares to cover tax obligations.

Summary

• Ryan Preblick, Chief Financial Officer of Indivior Pharmaceuticals, Inc. (INDV), reported transactions related to his beneficial ownership.
• On March 14, 2026, 6,302 Restricted Stock Units (RSUs) vested and converted into an equal number of common stock shares.
• These RSUs were originally granted on March 14, 2024, under the Indivior Group Deferred Bonus Plan 2018.
• Concurrently, 2,843 shares of common stock were disposed of to satisfy tax withholding obligations associated with the RSU vesting.
• The shares disposed for tax purposes were valued at $31.11 per share.
• Following these transactions, Ryan Preblick's direct beneficial ownership of Indivior common stock stands at 320,751 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. The RSU vesting is a positive for executive compensation, but the associated tax sale is a routine, non-discretionary transaction that does not reflect a change in company outlook.

Positives

• The vesting of 6,302 Restricted Stock Units (RSUs) represents a significant component of executive compensation, aligning management's interests with shareholder value over time.

Negatives

• A portion of the vested shares (2,843 shares) was sold to cover tax withholding obligations, which is a routine event and not indicative of a negative outlook on the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that this Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and the subsequent sale of shares to cover tax liabilities. Such transactions are common for executives receiving equity compensation and typically do not signal a change in company fundamentals or strategic direction.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-scheduled compensation event for an executive, not a discretionary sale indicating a change in sentiment.
• Employees: Reinforces the company's executive compensation structure, which often includes equity incentives.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving the vesting of restricted stock units and the sale of shares to cover tax obligations. Such an event does not provide new information that would alter the fundamental investment thesis for Indivior Pharmaceuticals, Inc. Therefore, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment strategy.

Keywords

Indivior Pharmaceuticals, INDV, Ryan Preblick, CFO, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Share Sale, Tax Withholding, Beneficial Ownership